hengrui glp-1 💊 ORAL UPDATE 💊 Kailera/Hengrui's HRS-7535 showed 9.8% weight loss in a 44-week Phase 3 trial in China. 🇨🇳 While effective and free of hepatotoxicity, high rates of nausea (70%) and Kailera, Hengrui to advance oral

The extraordinary case of the cancer drug Keytruda may offer insight into the potential road ahead for GLP-1s

These effects explain why patients often experience reduced cravings and a natural decline in caloric intake

Suddenly stopping these medications may lead to changes in blood sugar levels and appetite regulation

Cardiovascular outcome trials have established benefits for specific agents: the LEADER trial for liraglutide, SUSTAIN-6 for injectable semaglutide, and REWIND for dulaglutide demonstrated reduced risk of major adverse cardiovascular events in patients with type 2 diabetes

This is why buying from brands that provide clear labelling and third-party testing matters: it is the main quality check available to consumers in the absence of pre-approval

doi: 10.1080/00325481.2020.1798099 207 PiccoliGFMesquitaLASteinCAzizMZoldanMDegobiNAHet al